Faster Delivery for Induction With Misoprostol Plus Cervical Foley

Share this content:
Faster Delivery for Induction With Misoprostol Plus Cervical Foley
Faster Delivery for Induction With Misoprostol Plus Cervical Foley

THURSDAY, Nov. 10, 2016 (HealthDay News) -- For women undergoing induction, receipt of misoprostol-cervical Foley is associated with an increased likelihood of delivery before those receiving either method alone, according to a study published in the December issue of Obstetrics & Gynecology.

Lisa D. Levine, M.D., from the University of Pennsylvania Perelman School of Medicine in Philadelphia, and colleagues conducted a randomized trial comparing four induction methods: misoprostol alone, Foley alone, misoprostol-cervical Foley concurrently, and Foley-oxytocin concurrently. To compare the groups pairwise, a sample size of 123 per group was planned (492 patients overall); 491 were randomized and analyzed.

The researchers found that combination methods achieved a faster median time to delivery than single-agent methods (misoprostol-Foley, 13.1 hours; Foley-oxytocin, 14.5 hours; misoprostol, 17.6 hours; and Foley, 17.7 hours; P < 0.001). Women who received misoprostol-Foley were almost twice as likely to deliver before those who received misoprostol alone and Foley alone after censoring for cesarean delivery and adjusting for parity (hazard ratios, 1.92 and 1.87, respectively); there was no significant difference for Foley-oxytocin versus single-agent methods.

"After censoring for cesarean delivery and adjusting for parity, misoprostol-cervical Foley resulted in twice the chance of delivering before either single-agent method," the authors write.

One author disclosed financial ties to the pharmaceutical industry.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Salmonella Outbreak in 26 States Linked to Raw Turkey Products

<i>Salmonella</i> Outbreak in 26 States Linked to Raw ...

40 individuals have been hospitalized to date; no deaths have been reported

FDA Recalls Drugs Containing Active Ingredient Valsartan

FDA Recalls Drugs Containing Active Ingredient Valsartan

All lots of non-expired products that contain valsartan supplied by Zhejiang Huahai being recalled

Atopic Dermatitis Places Heavy Burden on Patients

Atopic Dermatitis Places Heavy Burden on Patients

Overall and mental health, life satisfaction all impacted, especially for moderate, severe disease

is free, fast, and customized just for you!




Already a member?

Sign In Now »